BOULDER, Colo., July 27, 2016 /PRNewswire/ -- Array BioPharma
Inc. (Nasdaq: ARRY) will report financial results for the
fourth quarter and full year of fiscal 2016 and hold a conference
call to discuss those results on Thursday,
August 4, 2016. Ron Squarer, Chief Executive Officer,
will lead the call.
|
Date:
|
Thursday, August 4,
2016
|
|
Time:
|
9:00 a.m. Eastern
Time
|
|
Toll-Free:
|
(844)
464-3927
|
|
Toll:
|
(765)
507-2598
|
|
Pass
Code:
|
55520532
|
|
Webcast, including
Replay and Conference Call
Slides:
http://edge.media-server.com/m/p/9vx5kngz
|
About Array BioPharma
Array BioPharma Inc. is a
biopharmaceutical company focused on the discovery, development and
commercialization of targeted small molecule drugs to treat
patients afflicted with cancer. Six registration studies are
currently advancing related to three cancer drugs. These programs
include binimetinib (MEK162), encorafenib (LGX818) and selumetinib
(AstraZeneca). For more information on Array, please go to
www.arraybiopharma.com.
|
CONTACT:
|
Tricia
Haugeto
|
|
Array BioPharma
Inc.
|
|
(303)
386-1193
|
|
thaugeto@arraybiopharma.com
|
Logo -
http://photos.prnewswire.com/prnh/20121029/LA02195LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/array-biopharma-to-report-financial-results-for-the-fourth-quarter-and-full-year-of-fiscal-2016-on-august-4-2016-300305147.html
SOURCE Array BioPharma Inc.